Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...

Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

As Dexcom seeks expanded coverage of its continuous glucose monitors (CGM) for people with Type 2 diabetes, it expects its Stelo users will shift. “What we hope for is that we can get insurance ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

That included stats showing Dexcom ... the FDA. Stelo’s features will also migrate to other systems, with the over-the-counter wearable acting as a gateway for people new to CGM as a whole.

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

In August, DexCom announced the availability of Stelo, the first over-the-counter CGM biosensor in the United States for people with type II diabetes who do not use insulin. The expansion in the ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from ...

In August, DexCom announced the availability of Stelo, the first over-the-counter CGM biosensor in the United States for people with type II diabetes who do not use insulin. The expansion in the ...